GenDx NGSgo Oncodentify

GenDx has added a new assay to its product portfolio, NGSgo Oncodentify. The test, developed in collaboration with the University Medical Center of Utrecht, identifies mutations in JAK2, CALR and MPL to determine prognosis and guide treatment decisions for patients with myeloproliferative neoplasms. Intended for use on Illumina sequencing platforms, the kit is the first of what the company said is a series of assays to detect somatic mutations related to hematological malignancies.

The assay is currently for research use only but GenDx said it is in the process of validating it as a clinical in vitro diagnostic.